2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 542

‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Abstract Number: 2600

‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis
Abstract Number: 492

‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA
Abstract Number: 134

‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort
Abstract Number: 2193

“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial
Abstract Number: 876

“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Abstract Number: 1157

#WomeninRheumatology: Is There a Speaker Gender Gap at ACR Meetings?
Abstract Number: 2218

1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis
Abstract Number: 2409

24-hour Activity Profiling in People Living with Arthritis: Habits Matter
Abstract Number: 2524

24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Abstract Number: 2776

5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Abstract Number: 1822

6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Abstract Number: 583

A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy
Abstract Number: 2835

A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Abstract Number: 1071

A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis

1
2
3
…
198
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].